Regeneron Pharmaceuticals Stock News

Single administration of CIDEB siRNA resulted in rapid, deep and durable reductions in liver fat by up to 80% that were sustained through 36 weeks

Regeneron stock popped Thursday after its Sanofi-partnered allergic conditions drug, Dupixent, easily beat third-quarter calls.

TARRYTOWN, N.Y., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial results for the third quarter of 2026 and provided a business update.

Updated agreement expands 2020 procurement agreement with BARDA for Regeneron's first-in-class antibody treatment for Orthoebolavirus zairense , adding value of approximately $270 million

Regeneron said on Monday it extended its agreement with a US health authority to ​provide additional supply of its Ebola ‌treatment, amid a growing outbreak in Africa.

Longer-term data reflecting nearly 4 years of follow-up show a further reduction in the risk of death from 14% to 37% for those initially treated with Libtayo, despite an 88% crossover from the placebo arm upon recurrence

Positive opinion supports reducing Libtayo dosing frequency from every three weeks to every six weeks after first 12 weeks of treatment